Meeting Banner
Abstract #1118

Non-Invasive Imaging Biomarkers of Tumor Response to XL184 Therapy

Benjamin A Hoff 1 , Jean-Christophe Brisset 2 , Stefanie Galbn 3 , Craig J Galbn 1 , and Brian D Ross 1

1 Radiology, University of Michigan, Ann Arbor, MI, United States, 2 New York University Langone, NY, United States, 3 Radiation Oncology, University of Michigan, MI, United States

Clinical response criteria (RECIST 1.1) considers boney metastases measuring >10mm without soft tissue involvement as unmeasurable. The clinical need for accurate therapeutic response measures is more pressing with the introduction of targeted therapies into standard of treatment. XL184 is a novel tyrosine kinase inhibitor that exhibits activity against mainly MET and VEGFR-2.1 We evaluated DW-MRI and CT pre- and post-therapy on a mouse model of bone-metastatic prostate cancer to assess early treatment response to this therapy. The therapeutic effect of XL184 was observed via several readouts, with mean tumor ADC increasing significantly over controls by day 3 post-therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here